Stay updated on Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page
- CheckyesterdayChange DetectedThe page’s footer revision indicator was updated from v3.5.2 to v3.5.3, reflecting a site/software version change rather than any change to the trial information displayed.SummaryDifference0.1%

- Check8 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded AA amyloidosis and multiple myeloma as related disease terms and included the Genetic and Rare Diseases Information Center as a resource.SummaryDifference0.2%

- Check37 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check73 days agoChange DetectedSite revision updated from v3.4.1 to v3.4.2; no changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.